Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Copeptin After Arginine Infusion in Polyuria-Polydipsia Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01879137
Recruitment Status : Completed
First Posted : June 17, 2013
Last Update Posted : July 11, 2017
Sponsor:
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland

Brief Summary:
the purpose of the study is to investigate whether arginine infusion is a new tool to differentiate patients with diabetes insipidus, primary polydipsia and healthy subjects.

Condition or disease
Healthy Polyuria-polydipsia Syndrome

Layout table for study information
Study Type : Observational
Actual Enrollment : 60 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Copeptin After Arginine Infusion for the Differential Diagnosis of the Polyuria-Polydipsia Syndrome ''The CARGO-Study''
Study Start Date : June 2013
Actual Primary Completion Date : May 2017
Actual Study Completion Date : May 2017

Resource links provided by the National Library of Medicine


Group/Cohort
healthy adults
Patients with a polyuria-polydipsia syndrome



Primary Outcome Measures :
  1. Discriminative value of copeptin after arginine infusion in the differential diagnosis of polyuria-polydipsia syndrome. [ Time Frame: up to 120 minutes after the Arginine infusion. ]

Biospecimen Description:
Serum EDTA


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy adults Patients with polyuria-polydipsia syndrome
Criteria

Inclusion Criteria:

  1. Age over 18 years
  2. No medication except hormonal contraception

Exclusion Criteria:

  1. Evidence of any acute illness
  2. Subjects refusing or unable to give written informed consent
  3. Pregnancy
  4. Any evidence of disordered drinking habits and diuresis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01879137


Locations
Layout table for location information
Switzerland
University Hospital Basel
Basel, Basel-Stadt, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Layout table for investigator information
Principal Investigator: Mirjam Christ-Crain, Prof. MD University Hospital, Basel, Switzerland
Layout table for additonal information
Responsible Party: University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT01879137    
Other Study ID Numbers: CARGO 2013
First Posted: June 17, 2013    Key Record Dates
Last Update Posted: July 11, 2017
Last Verified: July 2017
Keywords provided by University Hospital, Basel, Switzerland:
Copeptin
Arginin stimulation test
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Insipidus
Polyuria
Syndrome
Polydipsia
Disease
Pathologic Processes
Kidney Diseases
Urologic Diseases
Pituitary Diseases
Endocrine System Diseases
Urination Disorders
Urological Manifestations